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Laura Hyrup Møller,a Andre´ Macherius,b Thomas Hesselhøj Hansen,b
Hanne Mørck Nielsen,a Claus Cornett,a Jesper Østergaard,a Stefan Stu¨rupa
and Bente Gammelgaard*a
A method for quantiﬁcation of a pharmaceutical peptide in human plasma was developed using gradient
elution LC-ICP-MS. A membrane desolvation (MD) system was applied to remove organic solvents from
the eluent prior to the detection as SO+ in the dynamic reaction cell (DRC) of the ICP-DRC-MS
instrument and subsequent quantiﬁcation by post-column isotope dilution (IDA). Plasma proteins were
precipitated prior to analysis. Analytical ﬁgures of merit including linearity, precision, LOD, LOQ and
accuracy were considered satisfactory for analysis of plasma samples. The selectivity of the developed
method was demonstrated for ﬁve pharmaceutically relevant peptides: desmopressin, penetratin,
substance P, PTH (1-34) and insulin. Preliminary experiments on an ICP-MS/MS system using oxygen to
reduce the eﬀect of organic solvents were also performed to compare sensitivity. The results of the
study demonstrated that LC-ICP-MS post-column IDA may constitute a valuable additional tool in
quantiﬁcation of non-labelled peptides in the early drug development oﬀering absolute quantiﬁcation
without need of species speciﬁc standards.Introduction
The interest in peptides and proteins as drugs and excipients is
continuously increasing in biomedical research. The number of
peptide therapeutics reaching preclinical and clinical trials
increases every year. Peptides are favorable as therapeutics as
they oﬀer good eﬃcacy, safety and tolerability due to their
composition of amino acids.1 During drug development,
parameters such as stability, pharmacokinetics andmetabolism
must be monitored; therefore, sensitive and selective analytical
methods are required. Quantitative analysis of peptides in
biological matrices is challenging due to the similarity of
pharmaceutical peptides to endogenous compounds. Peptide
quantication has predominantly been performed by uores-
cence detection (FLD) exploiting uorophores naturally present
in the peptide sequence or by adding a uorescent label.2
Additionally, immunoassays, e.g. ELISA, are widely used for
quantication of peptides and proteins.3 Nowadays, identica-
tion and quantication is predominantly performed by liquid
chromatography mass spectrometry (LC-MS). Analysis of
peptides by LC-MS in complex biological matrices such as
plasma demands thorough sample preparation and species
specic peptide standards for absolute quantication.4of Pharmacy, Denmark. E-mail: bente.
of Plant and Environmental Sciences,
hemistry 2016The large potential of inductively coupled plasma mass
spectrometry (ICP-MS) in quantitative analysis of biomolecules
has already been highlighted in a number of reviews.5–7
Hyphenated to a separation technique, ICP-MS is a powerful
technique for quantitative analysis of biomolecules oﬀering low
limits of detection, a wide dynamic range and in principle
species independent sensitivity, thus, quantication using
a single inorganic standard is possible. The premise of using
ICP-MS for detection is the presence of an ICP-MS detectable
element in the peptide structure such as sulfur (S), phosphorus
(P) or selenium (Se), otherwise an ICP-MS detectable label must
be inserted. Introduction of elemental labels as metal-chelating
moieties or metal aﬃnity tags has been widely reported.5,8
Labelling withmetals ensure high sensitivity and selectivity, but
the drawback of these approaches is alteration of the structure
and physicochemical properties of the peptide. Furthermore,
the stoichiometry of the label and the molecule must be
controlled and known for quantitative purposes. Unequivocal
stoichiometry is achieved using heteroelement tags, which are
covalently bound in the peptide structure. Recently, we intro-
duced Se as an elemental detection label for quantication of
peptides.9 By exchange of the S-containing amino acid methi-
onine (Met) with the Se-containing analogue selenomethionine
(SeMet) during peptide synthesis, we introduced a label causing
minimal alteration of the native peptide structure and physi-
cochemical properties.10 The most attractive approach would
therefore be to monitor a heteroelement in the native structure
of the peptide. S is present in the natural occurring amino acidsJ. Anal. At. Spectrom., 2016, 31, 1877–1884 | 1877
JAAS PaperMet and cysteine (Cys) and thus constituting a versatile label in
the majority of biomolecules, but measuring S in complex bio-
logical matrices by ICP-MS is not straightforward. The ioniza-
tion eﬃciency of S in the argon plasma is limited due to the
high rst ionization energy (10.357 eV). Furthermore, detection
of the main S isotope (32S, 94.99% (ref. 11)) is hampered by the
formation of polyatomic interferences in the plasma, mainly
dimers of oxygen (16O2
+). Diﬀerent instrumental setups and
approaches to overcome these interferences have been devel-
oped. One approach is to use a quadrupole based collision/
reaction cell ICP-MS instrument. By using xenon as collision gas
polyatomic interferences are removed by collision induced
dissociation and allows for measurement of 32S.12 The main
approach for collision/reaction cell instruments is to use oxygen
as reaction gas for the formation of sulfur oxide (32S16O+) which
is less interfered as compared to the S isotopes.13 The applica-
tion of high resolution sector eld (SF) instruments facilitates
the separation of the diﬀerent masses of 32S+ (m/z ¼ 31.9898)
and 16O16O+ (m/z ¼ 31.9721) can be separated at a resolution of
4000 (m/Dm).14,15 Recently, ICP-MS/MS was introduced oﬀering
improved removal of polyatomic interferences and further
reduction of the background level. The LOD of this instrument
has thus been reported to be lowered to the ng L1 range for S.16,17
Measurement of S in biological matrices demands hyphen-
ation of a separation method to the ICP-MS in order to separate
analytes from natural occurring S-species in the matrix. Peptide
separation is most oen performed by reversed-phase liquid
chromatography (RP-LC) and gradient elution using either
acetonitrile or methanol.18 The continuous change in organic
solvent load from the eluent is not readily compatible with ICP-MS
as it may cool the plasma, change ionization and thus potentially
change sensitivity. Exposure to very high concentrations of
organic solventmay even extinguish the plasma. Furthermore, the
introduction of organic solvents may cause carbon build-up on
the cones and decrease sensitivity over time.19,20 By application of
a membrane desolvation (MD) system the organic solvent is
removed from the eluent prior to introduction to the ICP-MS and
up to 100%methanol or acetonitrile at ow rates of 200 mL min1
are tolerated.21 Optimization of the MD is only possible for
a single concentration level of organic solvent and the removal of
eluent may therefore not be constant throughout the gradient,
causing problems in species unspecic calibration. Isotope dilu-
tion analysis (IDA) can be applied to overcome this problem.22 The
technique is based on measurement of the isotope ratios in
a sample spiked with a solution enriched with a minor natural
abundant isotope of the element. In species unspecic IDA, also
known as post-column IDA, the enriched isotope is added to the
chromatographic eluent aer separation of the sample.23 The
technique and the equations used in calculations have been
presented in a tutorial review by Rodriguez-Gonza´les.24 Sulfur post
column IDA has been applied in several studies regarding protein
quantication by ICP-MS.22,25,26 The number of quantitative
studies of peptides or proteins in complex biological matrices
using ICP-MS detection of sulfur is very limited. Konz et al.
developed a method for quantication of the peptide hepcidin in
human urine by post column IDA27 but, the majority of studies
does not report on using IDA for quantication.28–301878 | J. Anal. At. Spectrom., 2016, 31, 1877–1884The aim of this study was to examine if it is possible to
quantify therapeutically relevant levels of sulfur-containing
pharmaceutical peptides in human plasma samples by LC-ICP-
MS and post-column IDA.
Experimental
Instrumentation
ICP-DRC-MS. The ICP-MS instrument was an ELAN DRCe
(Perkin Elmer SCIEX, Norwalk, CT, USA). Oxygen was applied as
reaction gas with the following settings of the dynamic reaction
cell: cell gas ow 0.35 L min1 and Rpq 0.45. The sampler and
skimmer cones were made of nickel. Lens voltage and RF power
were optimized on a daily basis using a 100 mg S L1 sulfate
solution in mobile phase (35% v/v acetonitrile (ACN), 0.1% v/v
triuoroacetic acid (TFA)). Data acquisition settings for specia-
tion analysis were: dwell time 200 ms; sweeps per reading 1; and
readings per replicate were adjusted to t the time of the chro-
matographic run, 48SO+ and 50SO+ weremonitored. A desolvation
system (Aridus II, CETAC Technologies, Omaha, NE, USA)
equipped with a 200 mL min1 C-ow PFA concentric nebulizer
(CETAC Technologies) was employed to remove organic solvent
from the eluent. Desolvation system settings: spray chamber
temperature 110 C, desolvator temperature 160 C, sweep gas
ow 7 L min1 and nitrogen gas ow 3 mL min1.
ICP-MS/MS. The analyses were performed using an Agilent
8800 ICP-MS/MS instrument equipped with a quartz injector
torch with a 1.5 mm internal diameter (ID), platinum sampling
and skimmer cones, a brass skimmer base and an x-lens
(Agilent Technologies, Santa Clara, USA). An Ari Mist HP
nebulizer from Burgener Research (Mississauga, ON, Canada)
and a Peltier-cooled double-pass Scott type spray chamber at
5 C (Agilent Technologies) were used for sample introduc-
tion. The ICP-MS/MS parameters were optimized using
a sulfate solution containing 100 mg L1 S in mobile phase
(35% v/v acetonitrile, 0.1% v/v TFA). Monitoring them/z 48 and
50 for 48SO+ and 50SO+, respectively, the plasma conditions
were optimized automatically on a daily basis. The custom
tune function was applied for optimization of S in order to
improve the specic sensitivity. The carrier gas (Ar) ow rate
was set to 0.36 L min1 and the option gas, a blend of 20%
oxygen in argon, was added at a ratio of 34% to the plasma in
order to prevent a carbon build-up on the cones. The RF power
was 1600 W and the sampling depth 7.5 mm. The ICP-MS/MS
analyses were carried out applying the MS/MS mode and
oxygen as reaction gas at a cell gas ow of 35% (corresponding
to 0.35 mL min1).
LC-MD-ICP-DRC-MS. An Agilent 1100 series HPLC system
equipped with a degasser, a quaternary pump, an auto sampler
and a column oven was used for separation. The column was an
Aeris PEPTIDE XB-C18, 3.6 mm, 100  2.1 mm ID column pro-
tected by a C18-Peptide SecurityGuard ULTRA cartridge (Phe-
nomenex, Denmark). A multi-step gradient from 17–70% v/v of
acetonitrile (with 0.1% v/v TFA added) was applied (0–1 min:
17–20%, 1–5 min: 20–35%, 5.1–5.5 min: 38%, 5.6–6 min: 70%).
The ow rate was 200 mL min1, the column temperature 60 C,
and the injection volume 5 mL.This journal is © The Royal Society of Chemistry 2016
Paper JAASLC-ICP-MS/MS. A Dionex Ultimate 3000 UHPLC (Thermo
Scientic) equipped with a degasser, a quaternary pump, an auto
sampler and a thermostatted column compartment was used for
separation. The column and mobile phase were as described
above for LC-MD-ICP-DRC-MS, except the gradient was slightly
modied in order to move the peptide peak further away from
the front peak of the chromatogram (0–2 min: 17%, 2–3 min:
17–20%, 3–7 min: 20–35%, 7.1–7.5 min: 38%, 7.6–8 min: 70%).
Post column isotope dilution analysis. Quantication was
performed by post column IDA using an enriched 34S sulfate
standard solution 1000 mg S L1 in 35% v/v acetonitrile and
0.1% TFA. The 34S solution was infused constantly at a ow rate
of 10 mL min1 using a syringe pump, Harvard Apparatus
11 plus (Holliston, MA, USA) with a 5 mL syringe (Hamilton,
Bellefonte, PA. USA). The ow rate was corrected from mass per
minute to volume per minute using the relevant density. The
syringe pump was connected to the eluent ow from the HPLC
by a static mixing T-piece. The connection was made of PEEK
tubing with an inner diameter of 0.125 mm before mixing and
an inner diameter of 0.250 mm aer mixing. The experimental
isotope ratio 48SO/50SO was calculated on a daily basis by
measurement of 100 mg L1 S (sulfate) standard solution in
mobile phase (35% v/v ACN, 0.1% v/v TFA) and corrected for
blank signal and mass bias by using an exponential mathe-
matical model.24 Theoretical isotope ratios were calculated by
using the natural sulfur abundances.11 The dead time was cor-
rected automatically by the instruments. Mass ow chromato-
grams were obtained by application of the isotope dilution
equation to each data point of the chromatograms. Peak areas
were determined by integration of the chromatographic peaks
using the OriginPro 2015 soware (version 9.2, OriginLab,
Northampton, MA, USA).
Chemicals. Penetratin (Pen) was purchased from CASLO
(Lyngby, Denmark). Desmopressin European Pharmacopeia
certied reference standard (CRS) and substance P was
purchased from Sigma (St. Louis, MO, USA). PTH (1-34) was
from Bachem (Bubendorf, Switzerland) and human insulin was
kindly provided by Sano. ACN LC-MS grade was obtained from
Th. Geyer (Renningen, Germany), TFA from VWR International
(Lutterworth, UK), and trichloroacetic acid (TCA) from Fluka
Chemie, (Buchs, Switzerland). Human plasma was obtained
from the blood bank (Rigshospitalet, Copenhagen, Denmark).
The 99.90% 34S isotope was purchased from ChemGAS (Bou-
logne, France).
Standards. All peptide solutions were prepared in NoStick®
hydrophobic microtubes from SSI (Lodi, CA, USA). An amount
of 1 mg of Pen was dissolved in 1 mL of puried water. From
this solution, samples for validation were prepared. Desmo-
pressin CRS (0.94 mg as described in the certicate) was dis-
solved in 1 mL puried water. Substance P and PTH (1-34) was
dissolved in puried water and human insulin was dissolved in
0.1% TFA all in concentrations of 1 mg mL1.
The 34S enriched isotope standard was prepared by dissolv-
ing 20 mg elemental 34S in 3 mL sub boiled nitric acid (65%)
and digested in a microwave until a clear and colorless solution
was obtained. The solution was diluted with puried water toThis journal is © The Royal Society of Chemistry 201620mL. The total S concentration of the solution was determined
by reversed isotope dilution using a PlasmaCAL elemental
standard of S.Procedures
Sample preparation. Frozen human plasma was thawed and
ltered through a Q-max RR syringe lter, 0.45 mm cellulose
acetate membrane. Dened amounts of Pen were added to
human plasma reaching nal concentrations of 2–50 mM Pen in
50% plasma in puried water using NoStick® hydrophobic
microtubes. Plasma proteins were precipitated by addition of
10% v/v TCA in puried water in volume ratio 1 : 5 of TCA and
sample. The samples were centrifuged at 14 000g for 15 min at
room temperature. The supernatant was diluted 1 + 1 in eluent
(10% v/v ACN, 0.1% v/v TFA) prior to analysis.
Sample preparation by ultraltration was executed in 50%
human plasma diluted in puried water by addition of TFA to
a nal concentration of 0.5% and ultraltration through 500 mL
centrifugal lter units, Amicon® Ultra with a semi-permeable
membrane of molecular weight cut-oﬀ 30 kDa. The ultra
ltrates were diluted 1 + 1 in eluent (10% v/v ACN, 0.1% v/v TFA)
prior to analysis.
Sample preparation recovery. The recovery was determined
in triplicates by spiking 10 mM and 40 mM Pen into 50% plasma
before and aer sample preparation. Recoveries were calculated
as the ratio of peak areas of plasma spiked before and aer
sample preparation (mass ow chromatograms).
Linearity. Linearity was determined by addition of dened
amounts of Pen to plasma prior to sample preparation reaching
nal concentrations of: 2, 5, 10, 20 and 50 mM in 50% plasma.
The samples were diluted 1 + 1 in eluent (10% v/v ACN, 0.1% v/v
TFA) prior to analysis.
Precision. Precision was determined as the relative standard
deviation (RSD%) of ve injections of a 10 mM sample aer
sample preparation and dilution as described above.
Limit of detection (LOD) and limit of quantication (LOQ). A
sample of 2 mM Pen spiked into plasma prior to sample prep-
aration was analyzed (5 injections). The standard deviation of
the mass ow chromatogram peak areas was calculated and
LOD and LOQ determined as three times and ten times the
standard deviation, respectively.
Accuracy. Accuracy of the method was determined by anal-
ysis of 5 mM S (2.5 mM desmopressin Ph. Eur. CRS) (three
injections).
Selectivity. Selectivity of the chromatographic method was
demonstrated for ve S-containing, pharmaceutical peptides:
desmopressin, Pen, substance P, PTH (1-34) and human
insulin. The peptides were spiked individually in ultraltrated
plasma to a nal concentration of peptide corresponding to 10
mM S.Results and discussion
Method development
The aim of this study was to examine if it is possible to quantify
pharmaceutical S-containing peptides in human plasma byJ. Anal. At. Spectrom., 2016, 31, 1877–1884 | 1879
Fig. 1 Mass ﬂow chromatograms from LC-MD-ICP-DRC-MS analysis
of 50% plasma samples. Light blue: blank plasma, oﬀset by 1.2 ng
min1. Dark blue: 50 mMPen spiked in 50% plasma prior to sample pre-
treatment.
JAAS PaperLC-ICP-MS using the cell-penetrating peptide Pen as a model
compound. Reversed phase gradient separation usingmethanol
or acetonitrile is the preferred method for separation of
peptides.4 In order to overcome the challenges arising from
introduction of organic solvents to the ICP-MS, a membrane
desolvation (MD) system (Aridus II, Cetac) was applied. The use
of the MD system limits the ow rate of the separation method,
as only nebulizers with a ow rate up to 200 mL min1 are
available for sample introduction. Furthermore, the MD
extends the distance between the HPLC column and the ICP-MS
causing peak broadening. Narrow peaks and excellent resolu-
tion is therefore demanded for the separation when a MD
system is applied.
Recently we developed an LC-ICP-MS method applying
a linear methanol gradient (0.1% v/v acetic acid, 0.05% v/v TFA)
for separation of a Se-labelled analogue of Pen and its degra-
dation products during cell uptake studies.9 Separation of
S-containing peptides in human plasma is more challenging
due to the presence of large amounts of endogenous S
compounds in the sample matrix. In order to separate low
molecular weight S compounds and S-containing proteins in
plasma, a multi-step acetonitrile (0.1% v/v TFA) gradient was
developed for separation of Pen from S-containing plasma
constituents. The column temperature was set to 60 C to obtain
narrow peaks and improve resolution. Satisfactory peak shape
and separation of Pen from plasma components were obtained.
Quantication by post column isotope dilution analysis
The species independent sensitivity of LC-ICP-MS is lost when
gradient elution is applied, as the shi in organic content in the
eluent changes the sensitivity during elution of the species.
Thus, the instrument sensitivity of early eluting species will
diﬀer from later eluting species. In order to compensate for
these variations in sensitivity as well as dri of the instrument
signal, post column IDA was employed for absolute quanti-
cation (details are described in the Experimental section). The
mass bias factor (F) was estimated and applied in correction of
the experimental isotope ratios of 32S/34S. Subsequent to
correction, the isotope dilution equation24 was applied in the
entire chromatogram to obtain the mass ow data and the peak
areas were integrated. An example of a mass ow chromato-
gram obtained from MD-ICP-DRC-MS analysis of blank plasma
and plasma spiked with Pen is shown in Fig. 1.
Sample preparation
Plasma proteins should be removed prior to LC-ICP-MS analysis,
but it is important that the analyte remains in the sample with
a satisfactory and reproducible recovery of analyte. Working with
peptide-containing samples can be a challenge due to unspecic
adsorption of peptides to surfaces and other constituents of the
matrix e.g. proteins. Adsorption is oen dependent on the
specic side chains on the amino acids of the peptide and may
be reduced by choosing conditions which aﬀects the equilibrium
constant between the peptide and surfaces or between the
peptide and proteins which it may adsorb to.31 Pen contains
16 amino acids (RQIKIWFQNRRMKWKK-NH2) of which 7 are1880 | J. Anal. At. Spectrom., 2016, 31, 1877–1884basic residues, and thus have a net charge of +8 at physiological
pH. In order to reduce ionic interactions of the peptide with the
surroundings, negatively charged residues were reduced by
acidifying samples during sample pretreatment. Two diﬀerent
approaches for removal of plasma proteins were pursued;
precipitation and ultraltration. TCA (10% v/v, volume ratio 1 : 5)
was chosen as precipitation reagent, ensuring acidic conditions.
A protein precipitation eﬃciency above 99% has been reported
for TCA.32 To determine the recovery of peptide aer precipita-
tion, spiked plasma samples were precipitated and the areas
from the mass ow chromatograms compared to the areas of
plasma samples spiked aer protein precipitation. Recovery was
determined at two concentration levels, 10 mM and 40 mM Pen;
recoveries of 70.6  6.2% (n ¼ 3) and 69.2  4.0% (n ¼ 3) were
obtained, respectively. Chromatograms of plasma samples
showed that some S-containing protein still remained aer
precipitation with 10% TCA. For ultraltration, a semipermeable
membrane with a molecular weight cut-oﬀ (MWCO) value of
30 kDa was used and the plasma acidied (0.5% v/v TFA) prior to
ltration. S-containing plasma proteins were almost completely
removed by ultraltration, but the recovery of 10 mM Pen was
only 32.4  9.0%. Ultraltration is attractive due to the almost
complete removal of proteins, but recovery and repeatability of
Pen were not satisfactory. Therefore, protein precipitation with
10% v/v TCA was chosen for further experiments. The remaining
protein content aer precipitation is a drawback, but as Pen was
clearly separated from the protein residues, this was accepted.Selectivity
The selectivity of the chromatographic method was examined
for a number of pharmaceutically relevant biomolecules: des-
mopressin, Pen, substance P, PTH (1-34) and insulin (Table 1).
The species were all satisfactorily separated by extension of the
38% v/v ACN isocratic part of the gradient aer elution of Pen.
Chromatograms of the peptides are shown in Fig. 2. It must be
noted that the developed method for Pen is not directly appli-
cable to any peptide, as the properties of all peptides are
diﬀerent, the sample pre-treatment must be examined and
optimized for each peptide of interest.This journal is © The Royal Society of Chemistry 2016
Table 1 Peptides used for demonstration of selectivity
Peptide Mw No. of amino acids No. of S
Desmopressin 1069.22 9 2
Penetratin 2245.74 16 1
Substance P 1347.63 11 1
PTH (1-34) 4117.74 34 2
Insulin 5807.6 110 6
Paper JAASAnalytical gures of merit
The chromatographic method was validated for Pen using the
DRC instrument equipped with a MD system (MD-ICP-DRC-MS)
and quantication by post column IDA. Oxygen was applied as
reaction gas resulting in measurement of 32S16O+ at m/z 48. The
analytical gures of merit are summarised in Table 2.
Linearity was examined in order to demonstrate a linear
response in the applied concentration range. Pen was spiked
into 50% v/v human plasma followed by protein precipitation
reaching a nal concentration of 0.5–15 mM Pen (15–450 mg S
L1). Linearity was established with correlation coeﬃcients of
0.999. Precision was determined at two concentration levels (0.7
mM and 3.5 mM). For both concentrations the precision were
considered satisfactory.
LOD and LOQ were estimated and absolute LOD of 0.6 pmol
S and LOQ of 1.9 pmol S were obtained. The LOD is consid-
erably lower as compared to LODs reported by others using
ICP-DRC-MS instruments and oxygen as reaction gas. For
proteins, peptides or amino acids in standard solutions, LODs
in the range of 2.3–3.1 pmols have been reported.13,33,34 Only
a limited number of studies, where hyphenated ICP-MS
methods were used for absolute quantication of S in plasma,
has been described. Koellensperger et al. obtained an LOD of
62 pmol S in albumin in human plasma using a two dimen-
sional chromatographic system and ICP-DRC-MS.29 The
improved LOD obtained in this study is explained by the
application of the MD system. In the MD, the sample is heated
and all volatile matrix constituents removed through a semi-
permeable membrane. As the sample is evaporated in the MD,
the total amount of analyte is introduced into the ICP-MS.
Using a regular ICP-DRC-MS setup with a spray-chamber andFig. 2 MD-LC-ICP-DRC-MS chromatograms of S-containing peptides a
This journal is © The Royal Society of Chemistry 2016a concentric nebulizer, only 2% of the sample spray reaches the
detector.35
The method was developed for Pen, which is not yet part of
any approved drug formulation. The relevant plasma concen-
tration is therefore not dened. For a well-known drug
compound as human insulin, maximum plasma concentrations
of 200 mIU mL1 (1.2 mM insulin z 7.3 mM S) have been re-
ported aer a single dose of 0.1 IU kg1.36 The developed
method would be applicable in a similar experiment as the LOD
obtained in this study was 0.12 mM Pen (containing 1 S atom).
The species dependent LOD will improve with the presence of
multiple S atoms in the peptide. If peptides such as desmo-
pressin (2 S atoms) or insulin (6 S atoms) were quantied, the
LOD of the species would improve correspondingly.
As no certied standards are available for Pen, the accuracy
of the IDA method was determined using desmopressin (Ph.
Eur. CRS). Accurate quantication by IDA requires simulta-
neous interference free detection of two isotopes of S, in this
case 32S and 34S.25 Using oxygen as a reaction gas the interfer-
ences are limited by the formation of 32S16O+ and 34S16O+.
Possible spectral interferences include 48Ti+, 48Ca+, 36Ar12C+ and
31P16O1H+ whichmay aﬀect the 32S16O+ signal, while 34S16O+ can
be interfered by 50Ti+ if interferences are not removed in the
DRC.15
Giner Martinez-Sierra et al. demonstrated applicability of
using reaction cell technology and quantication of S (32S16O+)
by post column isotope dilution in aqueous solutions of
methionine with accuracies of 98% and 99%.22 In our laboratory
we have demonstrated accuracy of 98.2% for a certied sulfate
standard using ion chromatography with isocratic elution
hyphenated to the ICP-DRC-MS and quantication by post
column IDA. Thus, the interferences are not considered devas-
tating for the IDA quantication. The inuence of matrix
constituents from biological samples on IDA quantication is
not known.
Application of the MD with ICP-DRC-MS may induce other
challenges, as diﬀerences in sensitivity between species when
using an MD system are well known.21,37 In order to obtain
accurate quantication by IDA using a MD system, the isotope
spike (34S as sulfate) as well as the analyte (desmopressin or
Pen) must be stable in the MD system and exhibit similar
sensitivity. This was experimentally conrmed and has alsond protein (10 mM S) spiked into ultra-ﬁltrated human plasma.
J. Anal. At. Spectrom., 2016, 31, 1877–1884 | 1881
Table 2 Analytical ﬁgures of merit of RP chromatography of Pen in human plasma using an MD-ICP-DRC-MS instrument equipped with an MD
systems
RSD RSD Estimated LOD Estimated LOQ Linearity Accuracya
0.5 mM level 3.5 mM level 0.5–15 mM
4.0% 2.3% 0.6 pmol 1.9 pmol R2 0.999 102  2.7%
3.6 mg L1 12.0 mg L1
(n ¼ 5) (n ¼ 5) (n ¼ 5) (n ¼ 5) (n¼3)
a Accuracy determined for desmopressin (Ph. Eur. CRS).
JAAS Paperbeen reported by Feldmann and colleagues who demonstrated
equal and stable signals of sulfate and smaller peptides using
an MD-system.38ICP-MS/MS detection
The chromatographic method was transferred to an ICP-MS/MS
instrument in order to compare sensitivity. As this instrument
was equipped with another LC-system, the ACN-gradient was
slightly modied in order to move the Pen peak away from front
peak tailing. One of the reasons for applying the ICP-MS/MS
instrument was that this system can handle larger organic
solvent amounts by addition of oxygen (20% in argon) to the
plasma and therefore the more complicated MD set-up was
avoided. A mass ow chromatogram is shown in Fig. 3. A
comparison of the mass ow chromatograms from LC-MD-ICP-
DRC-MS (Fig. 1) and LC-ICP-MS/MS (Fig. 3) reveal that the Pen
peak is slightly broader using the ICP-DRC-MS, presumably
because of the MD system and the diﬀerent LC-equipment
applied.
The main purpose of transferring the developed method to
the ICP-MS/MS system was to compare sensitivity with the
MD-ICP-DRC-MS set-up. The absolute LOD obtained by the
ICP-MS/MS instrument was 0.5 pmol S and the absolute
LOQ 1.6 pmol S and thus comparable to the MD-ICP-DRC-MS
system.
In theory, interferences are even more eﬃciently removed in
the ICP-MS/MS due to the dual selection of m/z in the rst and
third quadrupole (Q1 and Q3). When measuring S, m/z 32 andFig. 3 Mass ﬂow chromatogram from LC-ICP-MS/MS. 50 mM Pen
spiked in 50% plasma prior to sample pre-treatment and 50% blank
plasma. Dark red: Pen in plasma, light red: blank plasma, oﬀset by1.2
ng min1.
1882 | J. Anal. At. Spectrom., 2016, 31, 1877–188434 are exclusively selected in Q1 while m/z 48 and 50 interfer-
ences are rejected. Only the selected ions reach the reaction cell
and react with O2 forming
32S16O+ and 34S16O+. Finally, in the
Q3, m/z 48 and m/z 50 are selected while the interferences 16O2
+
and 16O18O+ are rejected improving the background level.39
Furthermore less noise was observed in the ICP-MS/MS chro-
matograms as compared to the MD-ICP-DRC-MS chromato-
grams. The ICP-MS/MS system was therefore expected to
improve the LOD obtained by the ICP-DRC-MS. However, the
results demonstrated, that the application of the MD system
improved the LOD of the DRC-system to a level comparable to
the ICP-MS/MS. Application of the MD system with the ICP-MS/
MS might also improve the LOD of this instrument as more
sample is introduced and signal suppression from introduction
of organic solvent is avoided. However, the MD introduces
further complexity to the analytical system and increases the
requirements for optimization which is not desirable.
The LOD obtained for the ICP-MS/MS is in accordance with
the relatively few studies reported applying ICP-MS/MS
hyphenated to a separation technique. Recently, LODs of
0.7 pmol S and 1.3 pmol S were reported for S-containing amino
acids by LC-ICP-MS/MS analysis.34 By capillary LC-ICP-MS/MS,
an absolute LOD at fmol level has been reported.16,40 To the
authors best knowledge, no studies on quantication of exog-
enous S in human plasma by LC-ICP-MS/MS have yet been
published.
Precision of 8.1% and 5.6% were obtained with the ICP-MS/
MS system for 0.5 mM Pen and 3.5 mM Pen, respectively. This is
slightly worse as compared to the MD-ICP-DRC-MS. As observed
from the mass ow chromatograms in Fig. 1 and 3, the inten-
sities of the Pen peaks are comparable, but the noise level was
visibly improved using the ICP-MS/MS. The superior precision
obtained by the MD-ICP-DRC-MS was therefore unexpected but
may be explained by the settings of the data collection, as
considerable fewer data points were collected for each chro-
matographic peak during the LC-ICP-MS/MS analysis as
compared to the LC-MD-ICP-DRC-MS analysis.
The accuracy obtained by LC-ICP-MS/MS was, however, only
80.2%. The LC method was developed and thoroughly tested
using MD-ICP-DRC-MS and subsequently transferred to the
ICP-MS/MS system. Analyte adsorption to surfaces is an
important issue in peptide analysis and could be a source of the
poorer accuracy as the two systems were completely diﬀerent.
Thus, further experiments should be performed to examine this
discrepancy between accuracies in the set-ups.This journal is © The Royal Society of Chemistry 2016
Paper JAASConclusion
A reversed phase gradient LC-ICP-DRC-MS method using
a membrane desolvation system and post-column IDA was
developed for quantication of an S-containing peptide in
human plasma. The analytical gures of merit were considered
satisfactory for analysis of human plasma samples. The ob-
tained LOD was considerably improved as compared to LODs
reported in literature using an ICP-DRC-MS instrument. By
transferring the developed method to an ICP-MS/MS system,
comparable LOD and improved noise level was achieved, but
the accuracy was only 80.2%. Further optimization of the
LC-ICP-MS/MS system is thus needed in order to determine the
applicability of this method.
LC-ICP-MS analysis represents a promising tool for quanti-
cation of peptides and small proteins in complex biological
matrices. The possibility of quantifying peptides without
introduction of a detection label or need of species specic
standards is obviously attractive. The selectivity obtained with
this method emphasizes the potential as analytical technique
in peptide drug development. Compared to UV-detection,
ICP-MS oﬀers improved selectivity as only sulfur-containing
compounds are detected and may also be valuable for quanti-
cation of peptides with limited UV-absorbance. In addition,
LC-ICP-MS may oﬀer an alternative method in cases where
ELISA is not easily executed or specic antibodies are
unavailable.Acknowledgements
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